Elekta (OTCMKTS:EKTAY) Sees Unusually-High Trading Volume – Here’s Why

Elekta AB (OTCMKTS:EKTAY) shares saw strong trading volume on Tuesday . 125,889 shares changed hands during trading, an increase of 1,064% from the previous session’s volume of 10,819 shares.The stock last traded at $4.62 and had previously closed at $4.54.

Analyst Ratings Changes

EKTAY has been the topic of several research analyst reports. UBS Group assumed coverage on Elekta in a research report on Wednesday, September 3rd. They set a “sell” rating on the stock. Zacks Research upgraded Elekta from a “strong sell” rating to a “hold” rating in a research report on Tuesday, September 16th. Three equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Reduce”.

Elekta Stock Up 2.2%

The firm has a market capitalization of $1.71 billion, a PE ratio of 77.35 and a beta of 1.12. The company has a current ratio of 1.05, a quick ratio of 0.82 and a debt-to-equity ratio of 0.63. The firm has a 50-day moving average of $5.05 and a two-hundred day moving average of $5.05.

Elekta (OTCMKTS:EKTAY) last released its quarterly earnings results on Thursday, August 28th. The company reported $0.03 earnings per share for the quarter. The business had revenue of $379.64 million during the quarter. Elekta had a net margin of 1.40% and a return on equity of 11.49%. On average, equities research analysts forecast that Elekta AB will post 0.36 EPS for the current year.

Elekta Dividend Announcement

The business also recently disclosed a dividend, which was paid on Friday, September 26th. Investors of record on Tuesday, September 9th were issued a $0.0744 dividend. The ex-dividend date of this dividend was Monday, September 8th. This represents a yield of 289.0%. Elekta’s dividend payout ratio is presently 200.00%.

About Elekta

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services.